Nymox Pharmaceutical (NASDAQ:NYMX) Trading Up 10.2%

Nymox Pharmaceutical Corp (NASDAQ:NYMX) was up 10.2% during mid-day trading on Thursday . The stock traded as high as $2.28 and last traded at $2.17, approximately 207,100 shares traded hands during mid-day trading. An increase of 109% from the average daily volume of 98,966 shares. The stock had previously closed at $1.97.

Separately, ValuEngine downgraded shares of Nymox Pharmaceutical from a “buy” rating to a “hold” rating in a report on Thursday, October 10th.

The company has a debt-to-equity ratio of 0.03, a current ratio of 5.38 and a quick ratio of 5.36. The firm’s fifty day simple moving average is $1.90 and its 200-day simple moving average is $1.76.

Nymox Pharmaceutical (NASDAQ:NYMX) last announced its quarterly earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter. Nymox Pharmaceutical had a negative net margin of 12,408.26% and a negative return on equity of 189.25%. The business had revenue of $0.02 million during the quarter.

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Wedbush Securities Inc. lifted its holdings in shares of Nymox Pharmaceutical by 6.3% in the second quarter. Wedbush Securities Inc. now owns 120,935 shares of the biopharmaceutical company’s stock valued at $175,000 after purchasing an additional 7,200 shares in the last quarter. A.R.T. Advisors LLC purchased a new position in shares of Nymox Pharmaceutical during the second quarter valued at approximately $28,000. Morgan Stanley lifted its stake in shares of Nymox Pharmaceutical by 32.5% during the second quarter. Morgan Stanley now owns 110,694 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 27,160 shares during the period. Private Advisor Group LLC purchased a new position in shares of Nymox Pharmaceutical during the second quarter valued at approximately $55,000. Finally, Weiss Asset Management LP purchased a new position in shares of Nymox Pharmaceutical during the second quarter valued at approximately $72,000. 4.03% of the stock is currently owned by institutional investors.

About Nymox Pharmaceutical (NASDAQ:NYMX)

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease.

Further Reading: The four types of profit margin

Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.